Literature DB >> 19358084

Modeling thyroid cancer in the mouse.

X-G Zhu1, S-Y Cheng.   

Abstract

Thyroid carcinomas, the most common endocrine tumors in humans, have an increasing incidence in the U.S. and worldwide. There are four major types of thyroid cancers: papillary, follicular, anaplastic, and medullary carcinomas. In recent years, significant progress has been made in the identification of genetic alterations in thyroid carcinomas, particularly, papillary and medullary thyroid cancers. Mouse models of thyroid cancer are valuable tools in elucidating molecular genetic changes underlying thyroid carcinogenesis and in identifying potential molecular targets for therapeutic intervention. Representative mouse models of papillary, follicular, and medullary carcinomas are reviewed here with particular emphasis on those for follicular thyroid carcinomas. Challenges for further development in the modeling of thyroid cancer will also be discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19358084      PMCID: PMC3464089          DOI: 10.1055/s-0029-1215572

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  111 in total

1.  Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development.

Authors:  E C Collins; R Pannell; E M Simpson; A Forster; T H Rabbitts
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

Review 2.  Mechanistic data and risk assessment of selected toxic end points of the thyroid gland.

Authors:  C C Capen
Journal:  Toxicol Pathol       Date:  1997 Jan-Feb       Impact factor: 1.902

3.  Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T-antigen in transgenic mice.

Authors:  C Ledent; J Dumont; G Vassart; M Parmentier
Journal:  Endocrinology       Date:  1991-09       Impact factor: 4.736

4.  Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.

Authors:  Hao Ying; Hideyo Suzuki; Hiroko Furumoto; Robert Walker; Paul Meltzer; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2003-07-17       Impact factor: 4.944

5.  Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice.

Authors:  F M Michiels; B Caillou; M Talbot; F Dessarps-Freichey; M T Maunoury; M Schlumberger; L Mercken; R Monier; J Feunteun
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

Review 6.  RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

Review 7.  Dysregulated RET signaling in thyroid cancer.

Authors:  Maria Domenica Castellone; Massimo Santoro
Journal:  Endocrinol Metab Clin North Am       Date:  2008-06       Impact factor: 4.741

8.  Perturbed thyroid morphology and transient hypothyroidism symptoms in Hoxa5 mutant mice.

Authors:  Dominique Meunier; Josée Aubin; Lucie Jeannotte
Journal:  Dev Dyn       Date:  2003-07       Impact factor: 3.780

Review 9.  Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Expert Rev Mol Diagn       Date:  2008-01       Impact factor: 5.225

10.  Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism.

Authors:  C Ledent; J E Dumont; G Vassart; M Parmentier
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  2 in total

Review 1.  Thyroid stem cells--danger or resource?

Authors:  B Gibelli; Ama El-Fattah; G Giugliano; M Proh; E Grosso
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-12       Impact factor: 2.124

2.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.